You’re burning time and cash. Here’s why.
Too many teams pick a lab because the website looks tidy or the price sounds low, then scramble when results land late or the data’s useless. Don’t get stuck fixing someone else’s mistakes. Start by asking the right questions about scope, oversight, and how they handle surprises. If you want blunt, practical help, start by checking what a trusted preclinical CRO actually promises versus what they deliver.
Core questions that cut to the chase
Ask direct, concrete things you can verify: Who signs off on study protocols? Can you see past study reports and raw data? What controls and blinding were used? Who handles bioanalysis, pathology reads, and QA? Request timelines with milestones, not vague “weeks.” Demand names: principal investigator, study director, lab lead. If they dodge specifics, that’s a red flag.
Common pitfalls teams trip over
Assuming “GLP-like” is the same as GLP. Not confirming audit access. Overlooking sample handling and chain-of-custody. Budgeting only for nominal study fees and forgetting extra runs, assays, or pathology re-reads. Not clarifying who owns raw data and who pays for repeats. These slip-ups mean more time, more money, and lost credibility.
What to check about study design and data quality
Check for predefined statistical plans, acceptance criteria, and clear stopping rules. Ask for SOP references and the lab’s deviation history. Verify instrument calibration and batch records. Make sure they’ll provide raw files, not just summary PDFs. If results matter to regulators or partners, insist on third-party review options up front.
Timelines, costs, and real contingencies
Get a timeline with hard dates for protocol approval, study start, interim reviews, and final report delivery. Build in contingency buffers for missed animals, assay failures, or pathology disputes. Cost quotes must show line items for repeats, additional analyses, and shipping. If a vendor gives a flat lump sum without breakdown, ask for one before you sign.
Alternatives and trade-offs — when to DIY, outsource, or split work
Doing in-house work keeps control but ties up facilities and expertise. Outsourcing full-service reduces overhead but raises dependency. Splitting work (e.g., CRO for dosing and an independent lab for bioanalysis) gives checks and balances but increases coordination. Weigh your internal capacity, timeline pressure, and regulatory needs before deciding.
Experience that matters — how to verify it
I’ve seen outright failures and clean runs; you spot the difference by digging into past performance and regulator-facing experience. One useful benchmark is alignment with U.S. FDA nonclinical safety guidance — labs that understand that framework handle toxicology studies the way reviewers expect. For specifics on vendors that specialize in those toxicology workflows, look at a recognized preclinical toxicology CRO and compare their submitted study types and readout examples to what you need.
Decision checklist before signing
Get these signed off in writing: protocol approval process, named personnel, data access rights, QA audit options, timeline milestones with penalties or credits, detailed budget with change-order rules, and ownership of samples and raw data. Walk through a mock timeline with the study director and confirm a communication cadence you can live with.
Wrap-up — what this gets you
Ask hard questions early. Demand names, data, and clear timelines. Avoid vague promises and one-line quotes. Do this and you cut risk, save time, and actually get usable data. If you want a partner who matches that checklist without lip service, KCI Biotech fits the practical, accountable profile most teams need.